Mark Burkard, MD, PhD, discussed genomic gaps, extreme survivors of metastatic breast cancer, and how minimal residual disease testing may refine care.
|Videos|December 12, 2018
KATHERINE Results Back New Adjuvant Standard for HER2+ Breast Cancer
Author(s)Charles E. Geyer Jr, MD
Dr. Charles Geyer discusses the phase III KATHERINE trial, which compared ado-trastuzumab emtansine vs trastuzumab in HER2-positive early breast cancer.
Advertisement
Dr. Charles Geyer discusses the phase III KATHERINE trial, which compared ado-trastuzumab emtansine vs trastuzumab in HER2-positive early breast cancer.
Advertisement
Related to this article
Hope S. Rugo, MD, discussed KEYNOTE-B49 data showing pembrolizumab plus chemotherapy improved PFS in PD-L1-positive HR+/HER2- breast cancer.
Jan Kitajewski, PhD, discusses how an ancestry-linked blood type may influence triple-negative breast cancer outcomes and clinical trial eligibility.
Black women die from breast cancer at rates 40% higher than white women — and are still missing from the trials that could help. Dr. Coral Omene on why.
The European Commission approved adjuvant T-DXd for HER2-positive early breast cancer with residual invasive disease based on DESTINY-Breast05 data.
Jan Kitajewski, PhD, explains how Notch inhibitors may sustain specialized tumor blood vessels that deliver immune cells and boost immuno-oncology.
In a phase 3 trial, the Breast Cancer Locator was noninferior to wire localization and lowered positive margin rates in nonpalpable breast cancer.
ASCENT-03 subgroup data show sacituzumab govitecan improved PFS vs chemotherapy across subgroups in untreated metastatic TNBC.
Advertisement
Advertisement
Trending on CancerNetwork
1
Closing the Gaps in Precision Oncology for Breast Cancer
2
KEYNOTE-B49 Points to a PD-L1-Defined Subset Benefiting From Immunotherapy in Breast Cancer
3
Navigating PD-L1–Low Gastroesophageal Cancer Treatment and Payer Challenges
4
Managing Patients With No Pathologic Response After Durvalumab Plus FLOT
5